Clinical Trial Update: Mogamulizumab Q4week Dosing in Participants With R/R CTCL [Phase 2]

View source ↗

Summary

Phase 2 trial update describes mogamulizumab dose every 4 weeks in relapsed/refractory cutaneous T-cell lymphoma participants; trial status is active not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory | Phase 2 | Status: ACTIVE_NOT_RECRUITING